Detail of > 132-69-4
- CAS Number:
- 132-69-4
- Name:
1-Propanamine,N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-, hydrochloride (1:1)
- Superlist Name:
- Benzidamine hydrochloride
- Formula:
- C19H23N3O.HCl
- Molecular Structure:
![Molecular Structure of 132-69-4 (1-Propanamine,N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-, hydrochloride (1:1))](http://www.lookchem.com/300w/2010/0618/132-69-4.jpg)
- Synonyms:
- 1-Propanamine,N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-, monohydrochloride(9CI);1-Benzyl-3-(3-dimethylaminopropoxy)-1H-indazole chloride;1-Benzyl-3-[3-(dimethylamino)propoxy]-1H-indazole hydrochloride;Algiflog;Andolex;Benalgin;Benciflam;Bendaminol;Benflogin;Benzyrin;Difflam;Difflam Cream;Dorinamin;Tamas;Tantum;
- Molecular Weight:
- 345.91
- EINECS:
- 205-076-0
- Melting Point:
- 147-153 °C
- Boiling Point:
- 474.4 °C at 760 mmHg
- Flash Point:
- 240.7 °C
- Solubility:
- soluble in water, alcohol, chloroform
- Appearance:
- the white crystalline powder
- Hazard Symbols:
Xn- Risk Codes:
- 20/21/22-36
- Safety:
- 26-36Details
Related products
- 132-69-41-Propanamine,N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-, hydrochloride (1:1)
- 642-72-81-Propanamine,N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-
- 456-14-4Benzenecarboximidamide,4-fluoro-, hydrochloride (1:1)
- 51761-16-12-Naphthalenol,7-amino-, hydrochloride (1:1)
- 935668-00-13-Azetidinol,3-ethyl-, hydrochloride (1:1)
- 202982-63-6Benzenemethanamine,4-chloro-2-fluoro-, hydrochloride (1:1)
- 920313-27-55-Thiazolecarboxaldehyde,2-amino-, hydrochloride (1:1)
- 372195-85-2Piperidine,4-butyl-, hydrochloride (1:1)
Other Products
- Titanium Dioxide Carbon black Glutathione Adenosine Cable pulling lubricant
- 13825-74-6Titanium,oxo[sulfato(2-)-kO,kO']-
- 566-19-87-Oxodehydroepiandrosterone
- 132-69-41-Propanamine,N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]-, hydrochloride (1:1)
- 75887-54-6Arteether
- 13241-28-6Chrysophanol 8-O-beta-D-glucoside
- 373-44-41,8-Octanediamine
- 74431-50-8Propanoic acid,3-(benzoylthio)-2-methyl-
- 5407-87-42-Pyridinamine, 4,6-dimethyl-
- 106560-14-94-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid, 6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-, (5R,6S)-
- 68239-06-5Cyclohexane,2-heptyl-3,4-bis(9-isocyanatononyl)-1-pentyl-
- 61432-55-11-Piperidinecarbothioicacid, S-(1-methyl-1-phenylethyl) ester
- 144222-34-4Benzenesulfonamide,N-[(1R,2R)-2-amino-1,2-diphenylethyl]-4-methyl-
- 63284-71-95-Pyrimidinemethanol, a-(2-chlorophenyl)-a-(4-fluorophenyl)-
- 2430-16-2Benzenehexanol
- 12672-51-4Cobalt hydroxide
Refine Suppliers Do you want your product ranking ahead? Know what is 'Top Seller'!
- Supplier Location:
China (Mainland)(14)
India(5)
Denmark(1)
- Business Type:
- Importer/Exporter(15)Lab/Research institutions(2)
- Certificates:
- ISO(1) Production License (0)
Please post your buying leads,so that our qualified suppliers
will soon contact you!
*Required Fields
Reference
- Dialysis method applied to benzydamine hydrochloride release in a cream
- Dialysis method applied to benzydamine hydrochloride release in a cream. Morales Lacarrere, Ivan; Gomez Carril, Martha (Lab. Tec. Med., Havana, Cuba). Rev. Cubana Farm., 17(3), 251-64 (Spanish) 1983. CODEN: RCUFAC. ISSN: 0034-7515. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) The release of benzydamine-HCl (I-HCl) [132-69-4] from 3 hydrophilic exptl. creams and a com. product was studied using a cellophane dialysis membrane in a cell. Statistics were used to det. I-HCl release in the different bases and for release rate studies. Both the dialysis method or chem. anal. were accurate and easy to carry out.
- Comparison of benzydamine hydrochloride and Salvia officinalis as an adjuvant local treatment to systemic nonsteroidal anti-inflammatory drug in controlling pain after tonsillectomy, adenoidectomy, or both: an open-label, single-blind, randomized clinical trial
- Comparison of benzydamine hydrochloride and Salvia officinalis as an adjuvant local treatment to systemic nonsteroidal anti-inflammatory drug in controlling pain after tonsillectomy, adenoidectomy, or both: an open-label, single-blind, randomized clinical trial. Lalicevic, Sinisa; Djordjevic, Ivan (Department of Otorhinolaryngology, Clinical Hospital Center "Dr. Dragisa Misovic-Dedinje", Belgrade, Yugoslavia). Current Therapeutic Research, 65(4), 360-372 (English) 2004 Excerpta Medica, Inc. CODEN: CTCEA9. ISSN: 0011-393X. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Benzydamine hydrochloride (BNZD) is a nonsteroidal anti-inflammatory drug (NSAID) used in an oral rinse formulation as an adjuvant to other NSAIDs in controlling postoperative pain after tonsillectomy, adenoidectomy, or both. Salvia officinalis (SO) is a topically applied herbal prepn. frequently used for the same indication. Pain, bleeding, and infection are the most common postoperative complications of tonsillectomy. The aim of this study was to compare the efficacy and tolerability of BNDZ with those of SO as adjuvant treatments in controlling postoperative pain. This open-label, single-blind, randomized clin. trial was conducted at the Department of Otorhinolaryngol., Clin. Hospital Center "Dr. Dragisa Misovic-Dedinje" (Belgrade, Serbia and Montenegro). Pediatric and adult patients undergoing tonsillectomy, adenoidectomy, or both were enrolled. Patients were randomized to receive BNZD or SO, in addn. to ibuprofen 20 mg/kg×d (children) or diclofenac 100 mg/d (adults). The primary end point was the proportion of patients with mild or no pain on postoperative days 1, 2, 4, and 7. Secondary end points were the incidences of infection, hemorrhage, and other adverse events. A total of 420 patients were enrolled (217 females, 203 males; 278 children, 142 adults; mean [SD] age, 6.2 [2.1] years [children] and 24.1 [9.8] years [adults] [range, 3-45 yr]). One hundred thirty-eight children received BNZD; 140 received SO (both in addn. to ibuprofen 20 mg/kg×d). Seventy-two adults received BNZD; 70 received SO (both in addn. to diclofenac 100 mg/d). A significantly lower proportion of children treated with adjuvant BNZD experienced moderate or severe pain than those treated with SO at each time point (P < 0. 132-69-4 is the cas registry number of certain chemical which is used as reagents here.01 at days 1 and 4; P < 0.001 at days 2 and 7). In children, the risk for postoperative infection was similar between BNZD and SO (abs. risk redn. [ARR], 6.9%; 95% CI, 6.4%-7.6%); however, the risk was reduced in adults (ARR, 19.0%; 95% CI, 16.5%-21.9%; P = 0.008). In this clin. trial of children and adults who underwent tonsillectomy, adenoidectomy, or both, BNZD, as an adjuvant to an NSAID, was more effective than SO in controlling postoperative pain and infection. The pain-reducing effect of BNZD was of quick onset and persisted for 1 wk after surgery. The safety profile of BNZD was comparable to that of SO, with the exception of postoperative infection in adults, for which BNZD was more efficacious. In particular, the use of BNZD was not assocd. with a high risk for early postoperative hemorrhage. .
- About us
- |
- Payment
- |
- Contact us
- |
- Links
- |
- Help Center
- |
- Disclaimer
- |
- Add to favorite
- | SiteMap
- |
- Product SiteMap
- |
- Manufacturers
- |
- Suppliers
©2008 LookChem.com,License:ICP NO.:Zhejiang10014259
[Hangzhou]86-571-85317600,85317603,85317620

